Emerging Growth Stocks Experience Significant Gains in After-Hours Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Should l Buy BFLY?
Source: NASDAQ.COM
Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.
Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.
Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.
Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFLY is 4.25 USD with a low forecast of 4.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.230
Low
4.00
Averages
4.25
High
4.50
Current: 3.230
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million, with proceeds allocated for critical commercialization activities and manufacturing scale-up, thereby accelerating the market introduction of its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into MRI-level 3D volumetric models, enhancing the accuracy of heart assessments, which is expected to significantly improve hospitals' diagnostic capabilities and patient treatment outcomes.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby driving market adoption and revenue growth.
- Executive Appointment: VentriPoint appointed David Swetlow as Chief Financial Officer, who brings over 15 years of management experience in the medical technology sector, a move seen as crucial for advancing the company's commercial strategy to shorten sales cycles and establish sustainable revenue streams.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million due to strong investor demand, with proceeds aimed at critical commercialization activities and scaling manufacturing to accelerate market entry for its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy, significantly enhancing the precision of heart assessments and promising measurable economic returns for hospitals, thereby boosting its competitive edge in the healthcare market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models that leverage real-world data to demonstrate potential savings for healthcare providers through process improvements and optimized resource allocation, further enhancing its market appeal.
- Executive Appointment: The appointment of David Swetlow as CFO, who brings over 15 years of senior management experience in medical technology, is viewed as a key step in driving market adoption and revenue growth, underscoring the company's commitment to future development.
See More
Freedom Capital Markets Initiates Buy Ratings on BFLY, SERV, and IBOC with Target Prices
- Butterfly Network Rating Upgrade: Freedom Capital Markets analyst Ilya Zubkov initiated coverage on Butterfly Network (NYSE:BFLY) with a Buy rating and a price target of $5, indicating a potential upside of 31% from its closing price of $3.82, reflecting optimistic market expectations for future growth.
- Serve Robotics Rating Upgrade: Analyst Dmitriy Pozdnyakov initiated coverage on Serve Robotics Inc. (NASDAQ:SERV) with a Buy rating and a price target of $16, representing a potential upside of approximately 58% from its Tuesday closing price of $10.10, indicating strong confidence in its technology and market prospects.
- International Bancshares Corporation Rating Upgrade: Analyst Amirlan Kalymbekov initiated coverage on International Bancshares Corporation (NASDAQ:IBOC) with a Buy rating and a price target of $85, suggesting a potential growth of about 27% from its current price of $66.91, reflecting a positive outlook on its financial health and market position.
- Analyst Rating Changes Overview: Freedom Capital Markets has issued Buy ratings for all three companies, indicating a general optimism about their future performance, which may attract more investor attention and potentially drive stock prices higher.
See More
Butterfly Network to Participate in 2026 J.P. Morgan Healthcare Conference
- Conference Participation: Butterfly Network will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, showcasing its innovations in digital health, which is expected to attract investor interest.
- Executive Attendance: Company executives Joseph DeVivo, John Doherty, and Megan Carlson will host investor meetings to present their latest ultrasound technology, further enhancing the company's market visibility in the medical imaging sector.
- Live Webcast: Butterfly will provide a live webcast of its presentation on January 15, with replay available until February 15, enhancing engagement and transparency with investors.
- Technological Innovation: Butterfly's ultrasound technology has received multiple awards, including the Best Medical Technology at the 2024 Prix Galien USA, demonstrating its leadership and ongoing innovation in the medical imaging field.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million, with proceeds allocated for critical commercialization activities and manufacturing scale-up, thereby accelerating the market introduction of its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into MRI-level 3D volumetric models, enhancing the accuracy of heart assessments, which is expected to significantly improve hospitals' diagnostic capabilities and patient treatment outcomes.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby driving market adoption and revenue growth.
- Executive Appointment: VentriPoint appointed David Swetlow as Chief Financial Officer, who brings over 15 years of management experience in the medical technology sector, a move seen as crucial for advancing the company's commercial strategy to shorten sales cycles and establish sustainable revenue streams.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million due to strong investor demand, with proceeds aimed at critical commercialization activities and scaling manufacturing to accelerate market entry for its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy, significantly enhancing the precision of heart assessments and promising measurable economic returns for hospitals, thereby boosting its competitive edge in the healthcare market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models that leverage real-world data to demonstrate potential savings for healthcare providers through process improvements and optimized resource allocation, further enhancing its market appeal.
- Executive Appointment: The appointment of David Swetlow as CFO, who brings over 15 years of senior management experience in medical technology, is viewed as a key step in driving market adoption and revenue growth, underscoring the company's commitment to future development.
See More
Freedom Capital Markets Initiates Buy Ratings on BFLY, SERV, and IBOC with Target Prices
- Butterfly Network Rating Upgrade: Freedom Capital Markets analyst Ilya Zubkov initiated coverage on Butterfly Network (NYSE:BFLY) with a Buy rating and a price target of $5, indicating a potential upside of 31% from its closing price of $3.82, reflecting optimistic market expectations for future growth.
- Serve Robotics Rating Upgrade: Analyst Dmitriy Pozdnyakov initiated coverage on Serve Robotics Inc. (NASDAQ:SERV) with a Buy rating and a price target of $16, representing a potential upside of approximately 58% from its Tuesday closing price of $10.10, indicating strong confidence in its technology and market prospects.
- International Bancshares Corporation Rating Upgrade: Analyst Amirlan Kalymbekov initiated coverage on International Bancshares Corporation (NASDAQ:IBOC) with a Buy rating and a price target of $85, suggesting a potential growth of about 27% from its current price of $66.91, reflecting a positive outlook on its financial health and market position.
- Analyst Rating Changes Overview: Freedom Capital Markets has issued Buy ratings for all three companies, indicating a general optimism about their future performance, which may attract more investor attention and potentially drive stock prices higher.
See More
Butterfly Network to Participate in 2026 J.P. Morgan Healthcare Conference
- Conference Participation: Butterfly Network will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, showcasing its innovations in digital health, which is expected to attract investor interest.
- Executive Attendance: Company executives Joseph DeVivo, John Doherty, and Megan Carlson will host investor meetings to present their latest ultrasound technology, further enhancing the company's market visibility in the medical imaging sector.
- Live Webcast: Butterfly will provide a live webcast of its presentation on January 15, with replay available until February 15, enhancing engagement and transparency with investors.
- Technological Innovation: Butterfly's ultrasound technology has received multiple awards, including the Best Medical Technology at the 2024 Prix Galien USA, demonstrating its leadership and ongoing innovation in the medical imaging field.
See More
